PreciseDx, a NYC-based innovator in oncology diagnostics leveraging Artificial Intelligence, raised $20.7M in Series B funding.
The round was led by Eventide Asset Management, with participation from Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.
The company intends to use the funds to support expanded commercialization efforts for PreciseBreast™ risk assessment.
PreciseDx is innovating oncology diagnostics by leveraging Artificial Intelligence for morphology-driven disease analysis. Combining AI with the patented Morphology Feature Array® (MFA), it provides access to disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
The funding follows a number of key achievements by PreciseDx, including completion of two successful validation studies (analytical and clinical); receipt of CLIA Standard approval and CLEP NYSDOH review on the PreciseBreast™ assessment; a Cost Impact Study published by the Journal of Medical Economics; and the addition of new key collaborations, such as UCLA, COTA and Baptist Health South Florida, and Baylor Scott & White Health.
